比伐卢定在先天性膈疝新生儿ECMO支持中的应用与结局
该多中心回顾性队列研究纳入2016至2023年48家美国儿童医院的1049例先天性膈疝ECMO新生儿,比伐卢定使用率从9.6%升至48.0%。在820例最终队列中,比伐卢定与肝素相比未改善院内死亡率(aOR 1.08,95%CI 0.42-2.82,P=0.87)或减少出血、血栓及神经系统并发症,但住院费用更高。
要点
- 比伐卢定使用率从2016年9.6%增至2023年48.0%。
- 比伐卢定与肝素相比未改善院内死亡率(aOR 1.08,95%CI 0.42-2.82)。
- 比伐卢定组住院费用中位数876,054美元,高于肝素组577,326美元。
核心结论
- 在先天性膈疝ECMO新生儿中,比伐卢定使用率显著增加,但与肝素相比未改善生存或减少ECMO相关并发症,且住院费用更高。
主要发现
- 1049例新生儿中,比伐卢定使用率从2016年9.6%上升至2023年48.0%。
- 最终队列820例中,398例院内死亡,死亡率为48.5%。
- 比伐卢定组住院费用中位数876,054美元(IQR 652,735-1,366,728),肝素组577,326美元(IQR 384,468-871,769),P<0.0001。
- 比伐卢定与院内死亡率无关(aOR 1.08,95%CI 0.42-2.82,P=0.87)。
- 比伐卢定与出血(aOR 1.43,95%CI 0.54-3.82,P=0.47)、血栓(aOR 1.88,95%CI 0.65-5.41,P=0.24)、神经系统并发症(aOR 2.00,95%CI 0.81-4.91,P=0.13)均无显著关联。
临床怎么用
- 对于先天性膈疝ECMO新生儿,选择比伐卢定抗凝时应权衡其较高费用与未证实的生存或并发症获益。
局限性
- 本研究为回顾性队列研究,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine national trends in bivalirudin use among neonates with congenital diaphragmatic hernia (CDH) supported with extracorporeal membrane oxygenation (ECMO) and to evaluate its association with mortality and morbidity. SUMMARY BACKGROUND DATA: Preliminary data suggest that first-line anticoagulation of the ECMO circuit with bivalirudin, a direct thrombin inhibitor, may improve outcomes in neonates with CDH. METHODS: This multicenter retrospective cohort study used data from 48 United States children's hospitals from January 1, 2016, to December 31, 2023. The analytic cohort included neonates with CDH supported with ECMO. Patients were categorized by anticoagulant exposure: bivalirudin or unfractionated heparin. The primary outcome was in-hospital mortality. Secondary outcomes included anticoagulant utilization and anticoagulant-associated morbidity. Multivariable logistic regression models were constructed after exclusion of extreme high-volume center outliers. RESULTS: Among 1,049 neonates, bivalirudin use increased significantly over time, from 9.6% in 2016 to 48.0% in 2023. In the final cohort of 820 neonates, 398 died in hospital (48.5% mortality). Median hospital charges were higher among neonates receiving bivalirudin [$876,054 (IQR, $652,735 - $1,366,728)] compared with heparin [$577,326 (IQR, $384,468 - $871,769); P<0.0001]. Bivalirudin use was not associated with in-hospital mortality [adjusted odds ratio (aOR), 1.08, 95% CI, 0.42-2.82; P=0.87], bleeding (aOR, 1.43, 95% CI, 0.54-3.82; P=0.47), thrombosis (aOR, 1.88; 95% CI, 0.65-5.41; P=0.24), or neurologic complications (aOR, 2.00; 95% CI, 0.81-4.91; P=0.13). CONCLUSIONS: Among neonates with CDH supported with ECMO, bivalirudin use increased substantially over the study period and was associated with higher hospital charges but not with improved survival or reduced ECMO-related morbidity compared with unfractionated heparin.
引用
- Sescleifer AM, Chidiac C, Hellmann ZJ, et al. Bivalirudin use and Outcomes in Neonates With Congenital Diaphragmatic Hernia Managed With Extracorporeal Life Support. Ann Surg. 2026. PMID: 42319156. doi:10.1097/SLA.0000000000007128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。